- UBS upgraded Apple (NASDAQ: AAPL) to Buy from Neutral and raised its target to $265 from $170, citing higher iPhone expectations, new partnerships, and likely upward revisions to Street estimates driven by gross margins.
- Wells Fargo upgraded Comcast (NASDAQ: CMCSA) to Outperform from Market Perform. The firm views a possible deal between end General Electric's (NYSE: GE) NBC Universal positively, as it thinks NBC will provide higher-margin growth for Comcast.
- Janney Montgomery upgraded Michael Baker (AMEX: BKR) to Buy from Neutral after the company completed the sale of its Energy business. The firm raised its target on shares to $46 from $40.
- Jefferies assumed coverage of Endo Pharma (NASDAQ: ENDP) and upgraded the stock to Buy from Hold. The firm cites valuation, a strong base business, and solid cash flow for the upgrade, and has a $30 target price on shares.
- Marten Transport (NASDAQ: MRTN) was upgraded to Overweight from Equal Weight at Stephens.
- U.S. Bancorp (NYSE: USB) was upgraded to Outperform from Market Perform at Keefe Bruyette.
endo pharma posts
FeedAnalyst upgrades, downgrades and initiations: AAPL, BAC, C, CMCSA, NOK, USB ...
Continue reading Analyst upgrades, downgrades and initiations: AAPL, BAC, C, CMCSA, NOK, USB ...
Analyst upgrades 1-9-07: Cheesecake Factory takes top honors
MOST NOTEWORTHY: Armor Holdings and Cheesecake Factory were the most notable upgrades this morning. - Lehman Brothers upgraded Armor Holdings (NYSE: AH) to Overweight from Equal Weight, following details of the President's $100B 2007 defense budget supplemental.
- Raymond James upgraded Cheesecake Factory (NASDAQ: CAKE) to Outperform from Market Perform following the company's better than expected forth quarter comps and revenues.
OTHER UPGRADES:
- Shares of Novel Inc (NASDAQ: NOVL) were upgraded to Outperform from Market Perform by JMP Securities; the firm said Novell's release of Open Enterprise Server 2 may help stop declines in the combined Netware/OES product lines.
- Jefferies upgraded shares of Endo Pharmaceuticals Hlds (NASDAQ: ENDP) to Buy from Hold, with a $35 target, to reflect improving Opana prescriptions and the resolution of the Penwest dispute, which the broker believes removes uncertainty and adds earnings visibility.
What Happened When Alex Kenjeev Paid His Student Loan in Cash
Preserve Your Budget by Freezing Foods -- Savings Experiment.gif)


